Adam Crystal, President of Research and Development at Tango Therapeutics, Inc. (NASDAQ:TNGX), filed a Form 4 on September 3, 2026, disclosing the exercise of stock options and the sale of 27,000 shares of common stock on September 1, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Adam Crystal exercised options covering 27,000 shares at an exercise price of $5.20 per share on September 1, 2026.
  • Share sale: Crystal sold 27,000 shares at a weighted average price of $22.367 per share, with individual sale prices ranging from $22.08 to $22.86 per share.
  • Post-transaction ownership: Following the transactions, Crystal directly holds 115,743 shares of common stock.
  • Remaining options: Crystal retains 260,040 stock options with an exercise price of $5.20 and an expiration date of March 1, 2033.
  • Pre-planned trading: According to the filing, both transactions were made pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025.
  • Vesting schedule: The underlying option vests over four years, with 25% vesting on February 27, 2024, and the remainder vesting in 36 equal monthly installments thereafter.

Crystal's Option Exercise and Share Sale at Tango Therapeutics

According to the Form 4 filed with the SEC, Adam Crystal, serving as President of Research and Development at Tango Therapeutics, Inc., executed two related transactions on September 1, 2026. Crystal first exercised stock options covering 27,000 shares of common stock at an exercise price of $5.20 per share, recorded as a transaction code "M" in the filing. Immediately following the exercise, Crystal disposed of those 27,000 shares through an open-market sale, recorded as transaction code "S."

The sale was executed at a weighted average price of $22.367 per share. The filing notes that shares were sold at prices ranging from $22.08 to $22.86 per share, and that full details on the number of shares sold at each price are available upon request to the SEC staff, the issuer, or a security holder. Both transactions were carried out under a Rule 10b5-1 trading plan that Crystal adopted on October 27, 2025, according to the filing. The form also indicates it was filed pursuant to a contract, instruction, or written plan satisfying the affirmative defense conditions of Rule 10b5-1(c).

Following the reported transactions, Crystal directly holds 115,743 shares of common stock. Crystal also retains 260,040 stock options with a $5.20 exercise price, expiring March 1, 2033. The filing was signed by Julie Fogarty as attorney-in-fact on September 3, 2026.

What Was Disclosed

The filing disclosed a same-day option exercise and share sale by Tango Therapeutics' President of R&D on September 1, 2026, conducted under a pre-established Rule 10b5-1 plan adopted in October 2025, resulting in direct beneficial ownership of 115,743 shares.